By performing a case study of a relapsed CLL patient, we show that ex vivo sensitivity to the Bcl-2 antagonist venetoclax correlates with in vivo response to the same treatment. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.